{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:12:41Z","timestamp":1790665961159,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients presenting with parkinsonian syndromes share many clinical features, which can make diagnosis difficult. This is important as atypical parkinsonian syndromes (APSs) such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal syndrome (CBS) carry a poor prognosis, compared with patients with Parkinson's disease (PD). In addition, there is overlap between APS and dementia diseases, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To use a panel of cerebrospinal fluid (CSF) biomarkers to differentiate patients with APS from PD and dementia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective cohort of 160 patients and 30 control participants were recruited from a single specialist centre. Patients were clinically diagnosed according to current consensus criteria. CSF samples were obtained from patients with clinical diagnoses of PD (n=31), PSP (n=33), CBS (n=14), MSA (n=31), AD (n=26) and FTD (n=16). Healthy, elderly participants (n=30) were included as controls. Total \u03c4 (t-\u03c4), phosphorylated \u03c4 (p-\u03c4), \u03b2-amyloid 1\u201342 (A\u03b242), neurofilament light chain (NFL), \u03b1-synuclein (\u03b1-syn), amyloid precursor protein soluble metabolites \u03b1 and \u03b2 (soluble amyloid precursor protein (sAPP)\u03b1, sAPP\u03b2) and two neuroinflammatory markers (monocyte chemoattractant protein-1 and YKL-40) were measured in CSF. A reverse stepwise regression analysis and the false discovery rate procedure were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CSF NFL (p&lt;0.001), sAPP\u03b1 (p&lt;0.001) and a-syn (p=0.003) independently predicted diagnosis of PD versus APS. Together, these nine biomarkers could differentiate patients with PD from APS with an area under the curve of 0.95 and subtypes of APS from one another. There was good discriminatory power between parkinsonian groups, dementia disorders and healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A panel of nine CSF biomarkers was able to differentiate APS from patients with PD and dementia. This may have important clinical utility in improving diagnostic accuracy, allowing better prognostication and earlier access to potential disease-modifying therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2014-309562","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T21:40:03Z","timestamp":1421271603000},"page":"1240-1247","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":231,"title":["A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes"],"prefix":"10.1136","volume":"86","author":[{"given":"N K","family":"Magdalinou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R W","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Mummery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H R","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Giunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T T","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,1,14]]},"reference":[{"key":"key-10.1136\/jnnp-2014-309562-1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2014-309562-2","first-page":"1159","article-title":"Secondary Parkinsonism","author":"Fahn","year":"1977","journal-title":"Scientic Approaches Clin Neurol"},{"key":"key-10.1136\/jnnp-2014-309562-3","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/brain\/awq123","article-title":"Does corticobasal degeneration exist? A clinicopathological re-evaluation","volume":"133","author":"Ling","year":"2010","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2014-309562-4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2165\/11640070-000000000-00000","article-title":"Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management","volume":"26","author":"Seltman","year":"2012","journal-title":"CNS Drugs"},{"key":"key-10.1136\/jnnp-2014-309562-5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/jnnp-2013-307539","article-title":"Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions","volume":"85","author":"Magdalinou","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2014-309562-6","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2014-309562-7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2011.08.012","article-title":"Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes","volume":"18","author":"Bech","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"key-10.1136\/jnnp-2014-309562-8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/ene.12326","article-title":"Cerebrospinal fluid alpha-synuclein levels in Parkinson's disease\u2014changed or unchanged?","volume":"21","author":"Zetterberg","year":"2014","journal-title":"Eur J Neurol"},{"key":"key-10.1136\/jnnp-2014-309562-9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jbmr.5650070506","article-title":"Identification of proteins secreted by human osteoblastic cells in culture","volume":"7","author":"Johansen","year":"1992","journal-title":"J Bone Miner Res"},{"key":"key-10.1136\/jnnp-2014-309562-10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2353\/ajpath.2008.080045","article-title":"YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor","volume":"173","author":"Bonneh-Barkay","year":"2008","journal-title":"Am J Pathol"},{"key":"key-10.1136\/jnnp-2014-309562-11","first-page":"226","article-title":"YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas","volume":"3","author":"Horbinski","year":"2010","journal-title":"Int J Clin Exp Pathol"},{"key":"key-10.1136\/jnnp-2014-309562-12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/187152710791011982","article-title":"Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease","volume":"9","author":"Hickman","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"key-10.1136\/jnnp-2014-309562-13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2014-309562-14","first-page":"509","article-title":"Corticobasal degeneration: clinical aspects","volume-title":"Handbook of clinical neurology","author":"Bak","year":"2008"},{"key":"key-10.1136\/jnnp-2014-309562-15","first-page":"670","volume-title":"Neurology","author":"Gilman","year":"2008"},{"key":"key-10.1136\/jnnp-2014-309562-16","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2014-309562-17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/jnnp.57.4.416","article-title":"The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia","volume":"57","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2014-309562-18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2014-309562-19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.10473","article-title":"The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations","volume":"18","author":"Disease, M.D.S.T.F.o.R.S.f.P.a.s","year":"2003","journal-title":"Mov Disord"},{"key":"key-10.1136\/jnnp-2014-309562-20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"key-10.1136\/jnnp-2014-309562-21","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2014-309562-22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.acn.2004.09.011","article-title":"Alternate-form reliability of the Dementia Rating Scale-2","volume":"20","author":"Schmidt","year":"2005","journal-title":"Arch Clin Neuropsychol"},{"key":"key-10.1136\/jnnp-2014-309562-23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/0306-9877(95)90228-7","article-title":"Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus","volume":"45","author":"Klipper-Aurbach","year":"1995","journal-title":"Med Hypotheses"},{"key":"key-10.1136\/jnnp-2014-309562-24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"key-10.1136\/jnnp-2014-309562-25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.parkreldis.2009.07.007","article-title":"Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinsons disease and atypical parkinsonian disorders","volume":"16","author":"Constantinescu","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"key-10.1136\/jnnp-2014-309562-26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neurobiolaging.2006.03.010","article-title":"CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease","volume":"28","author":"Abdo","year":"2007","journal-title":"Neurobiol Aging"},{"issue":"(Pt 4)","key":"key-10.1136\/jnnp-2014-309562-27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/brain\/awf080","article-title":"The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service","volume":"125","author":"Hughes","year":"2002","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2014-309562-28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archneur.1997.00550200007003","article-title":"What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study","volume":"54","author":"Litvan","year":"1997","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2014-309562-29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.58.2.160","article-title":"Clinicopathological study of 35 cases of multiple system atrophy","volume":"58","author":"Wenning","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"(Pt 3)","key":"key-10.1136\/jnnp-2014-309562-30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/brain\/118.3.759","article-title":"The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal","volume":"118","author":"Daniel","year":"1995","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2014-309562-31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.46.4.922","article-title":"Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)","volume":"46","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2014-309562-32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"\u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2014-309562-33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression","volume":"69","author":"Shi","year":"2011","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2014-309562-34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","article-title":"Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease","volume":"349","author":"Tokuda","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"key-10.1136\/jnnp-2014-309562-35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease","volume":"133","author":"Hong","year":"2010","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2014-309562-36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","article-title":"Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?","volume":"450","author":"Ohrfelt","year":"2009","journal-title":"Neurosci Lett"},{"key":"key-10.1136\/jnnp-2014-309562-37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0304-3940(00)01153-8","article-title":"Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects","volume":"287","author":"Borghi","year":"2000","journal-title":"Neurosci Lett"},{"key":"key-10.1136\/jnnp-2014-309562-38","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/mds.25589","article-title":"The glial marker YKL-40 is decreased in synucleinopathies","volume":"28","author":"Olsson","year":"2013","journal-title":"Mov Disord"},{"key":"key-10.1136\/jnnp-2014-309562-39","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1471-4159.2012.07911.x","article-title":"Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies","volume":"123","author":"Luk","year":"2012","journal-title":"J Neurochem"},{"key":"key-10.1136\/jnnp-2014-309562-40","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/WNL.0b013e318292a2d2","article-title":"The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy","volume":"80","author":"Massey","year":"2013","journal-title":"Neurology"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2014-309562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:00:01Z","timestamp":1601042401000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2014-309562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,14]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,10,14]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1136\/jnnp-2014-309562"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2014-309562","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,14]]}}}